Highlights of Vitreoretina

Register      Login

VOLUME 6 , ISSUE 4 ( December, 2013 ) > List of Articles

REVIEW ARTICLE

Novedades de AREDS en la Degeneración Macular Asociada a la Edad

Paul A. Sieving

Citation Information : Sieving PA. Novedades de AREDS en la Degeneración Macular Asociada a la Edad. 2013; 6 (4):15-17.

DOI: 10.5005/hov-10102-06404

Published Online: 26-12-2020

Copyright Statement:  Copyright © 2013; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

PDF Share
  1. National Eye Institute. Statistics and Data. Available at: www.nei.nih. gov/eyedata. Accessed November 14, 2007.
  2. The Eye Disease Prevalence Research Group. Cause and prevalence of visual impairment among adults in US. Arch Ophthlamol. 2004 Apr;122(4):477-85.
  3. Hogg R, Chakravarthy U. Age-related macular degeneration and micronutrients antioxidants. Curr Eye Res. 2004 Dec;29(6):387-401.
  4. Allen MJ, Jarding JB, Zehner. Macular degeneration treatment with nutrients and micro current electricity. J Orthomolec Med. 1998;13:211-14.
  5. Seddon JM, Ajani UA, Sperduto R. Dietary carotenoids, vitamins A, C, and E, and advanced AMD: Eye disease case control study. JAMA. 1994 Nov 9;272(18):1413-20.
  6. AREDS Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with Vitamin C and E, beta carotene, and zinc for AMD and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001 Oct;119(10):1417-36.
  7. AREDS Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with Vitamin C and E, beta carotene, and zinc for AMD and vision loss: AREDS report no. 9. Arch Ophthalmol. 2001 Oct;119(10):1439-52.
  8. Clemons TE, Chew EY, Bressler SB, et al. Research group national eye institute visual function questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS report no. 10. Arch Ophthalmol. 2003 Feb;121(2):211-7.
  9. Richer S, Stiles W, Statkute L. Double-masked, placebo-controlled, randomized trial of lutein and antioxidants supplementation in the intervention of atrophic AMD: Veterans LAST study. Optometry. 2004 Apr;75(4):216-30.
  10. SanGiovanni JP, Chew EY, Clemons TE, et al. The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No.
  11. Arch Ophthalmol. 2007 Sep;125(9):1225-32.
  12. SanGiovanni JP, Chew EW, Argon E, et al The relationship of dietary omega-3 long-chain polyunsaturated fatty acid intake with incident age-related macular degeneration: AREDS report no. 23.Arch Opthlamol. 2008 Sep;126(9):1274-9.
  13. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013 May 15:309(19):2005-15.
  14. Smigel K. Beta carotene fails to prevent cancer in two major studies: CARET intervention stopped. J Natl Cancer Inst. 1996 Feb 21;88(3- 4):145.
  15. The Age-Related Eye Disease Study 2 (AREDS2) Research Group. Lutein/Zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report No. 4. JAMA Ophthalmol. 2013 May 5:1-7.
  16. AREDS 2 Research Group. The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology. 2012 Nov;119(11):2282-9.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.